
Fabula Capital
Fabula Capital is a venture capital firm based in Ipanema, Brazil. This profile covers what we know about Fabula Capital and how founders can get in front of it in 2026.
Fabula Capital manages equity investment portfolios for business leaders and families, focusing on long-term wealth growth.
- Location
- Ipanema, Brazil
- Team size
- 1-10
How to pitch Fabula Capital
The founders who hear back from Fabula Capital lead with traction and a clear ask that matches its stage, not a generic mass email. Build a targeted, verified list, write a personalized note, and track who opens it, all in one place.
Connect with Fabula Capital
About this profile
This profile is part of Round Funded, an investor database and outreach platform for founders. It covers 60,000+ active VCs, angels, family offices and accelerators with verified contacts, lets you send pitches from your own Gmail, and includes a free Data Room for your raise. How this data is built.
Cite this page
Round Funded. "Fabula Capital." Round Funded investor database, updated October 19, 2026.
Stable URL, it will not change: https://www.roundfunded.com/en/vc/fabula-capital
Frequently Asked Questions
What is Fabula Capital?
Fabula Capital is a venture capital firm based in Ipanema, Brazil. Round Funded tracks its focus, stage, and activity alongside thousands of active investors.
Where is Fabula Capital based?
Fabula Capital is based in Ipanema, Brazil. You can reach out from anywhere with a pitch that matches its focus.
How do I contact Fabula Capital?
Unlock a verified email for Fabula Capital and reach out with a personalized pitch on Round Funded. We show only deliverable contacts, so your outreach does not bounce.
What is Round Funded?
Round Funded is an investor database and outreach platform for startup founders. It lists 60,000+ active investors with verified contacts, filtered to recent investment activity, and lets founders send personalized pitches from their own Gmail, track replies, and share a free Data Room. Round+ starts at $99 per month with a 3-day trial.